CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.57
−7.75%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.97
From 52W high−70.62%
Volume2.01M
Market cap$69.05M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.97
From 52W high
−70.62%
Volume
2.01M
Market cap
$69.05M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
20.8
MomentumView details →
1D Return
−7.75%
YTD Return
−53.93%
SummaryUpdated Jun 1, 2026
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a biopharmaceutical company founded in 2009 and headquartered in Norwood, Massachusetts. The company went public in October 2014 and focuses on developing innovative immune modulators for treating immuno-oncology and fibrosis diseases. Corbus operates as a clinical-stage biotechnology company, meaning it is primarily engaged in research and development activities rather than commercial product sales, with multiple drug candidates in various stages of clinical trials.
Similar companies
Latest newsMore news →
Corbus Pharmaceuticals announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701 in second-line and beyond oropharyngeal squamous cell carcinoma.36d agoCorbus Pharmaceuticals Holdings reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment, with the drug avoiding depressive effects.51d ago